Bio-Techne Corporation with ticker code (TECH) now have 13 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 120 and 88 suggesting an average Analsyt target price of $101.20. Given that the stocks previous close was at $84.21 this is indicating there is a potential upside of 20.2%. Also worth taking note is the 50 day moving average now sits at $78.76 and the 200 moving average now moves to $79.72. The market capitalization for the company is 13.10B. The stock price for Iron Mountain Incorporated is 83.21 USD
The potential market cap would be $15,743,422,416 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 49.53, revenue per share of 7.16 and a 7.11% return on assets.
Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.
